Pfizer (PFE) reported ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in Phase 2b trial

Pfizer's report on its ultra-long-acting injectable GLP-1 RA indicates promising results in its Phase 2b trial, showcasing sustained weight loss with monthly dosing.

Newsquawk StaffPublished On the live feed at 10 more headlines followed before this page went public
Newsquawk headlinesUTC

Pfizer Inc. (PFE) Q4 2025 (USD): Adj. EPS 0.66 (exp. 0.58), Revenue 17.6bln (exp. 16.85bln); FY26 revenue view 59.5-62.5bln (exp. 61.94bln), FY26 EPS 2.80-3.00 (exp. 2.97)

Ukraine's President Zelensky calls for additional support following discussion with NATO's Rutte

Pfizer (PFE) reported ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in Phase 2b trial

China's Premier Li to meet with Logitech's (LOGN SW) CEO

Merck & Co. (MRK) Q4 2025 (USD): adj. EPS 2.04 (exp. 2.01), Revenue 16.4bln (exp. 16.20bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This outcome could enhance Pfizer's portfolio, potentially impacting its market position within the growing diabetes and obesity treatments sector, leading to increased investor interest and possibly a positive shift in its stock trajectory.

Related headlines

The whole workspace, free to try.

Try it free